New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Immutep Limited

Contributing Author

Recent Articles by Immutep Limited

Oct-13	Immutep Announces Successful Completion of FDA Project Optimus Requirements IMMP GlobeNewswire
Oct-09	Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer IMMP GlobeNewswire
Sep-22	Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti IMMP GlobeNewswire
Sep-08	Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 IMMP GlobeNewswire
Aug-05	Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1 IMMP GlobeNewswire
Jul-30	Immutep Quarterly Activities Report Q4 FY25 IMMP GlobeNewswire
Jul-29	Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer IMMP GlobeNewswire
Jul-28	Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025 IMMP GlobeNewswire
Jun-23	Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases IMMP GlobeNewswire
May-27	Immutep's Efti with Radiotherapy & KEYTRUDA (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma IMMP GlobeNewswire
May-15	Immutep's Efti with KEYTRUDA (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer IMMP GlobeNewswire
May-05	Immutep's Efti in Combination with KEYTRUDA (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1 IMMP GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.